20 patients in each P1b arm with dox sensitive, naive tumours will show clear efficacy &amp; ensure #AVCT has plenty of optionality for partnering deals &amp; perhaps an early takeover. In the meantime once DX sold Avacta should assure the market it has sufficient cash for audit sign off